Axonyx, Inc.

SPARKS, NV / ACCESSWIRE / September 19, 2023 / Ludwig (OTC:LUDG), a provider of innovative medical technologies, announced today Marvin S. Hausman MD has joined Ludwig Enterprises, Inc as Chief Executive Officer. "I am excited about the research and commercial direction of Ludwig and its new subsidiary Exousia AI," stated Dr. Hausman. "Our game changing mRNA technology has the potential to save lives and significantly lower healthcare budgets." Marvin S. Hausman, M.D. has served as a key consultant to our company since July 2022. Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol Myers International, Mead Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx. An accomplished executive with domestic and international experience, Dr. Hausman successfully executed acquisitions of breakthrough medical technology, in conjunction with the formation, funding and launch of several corporations. He is a co-founder of Medco Research Inc., a NYSE biopharmaceutical company acquired by King Pharmaceutical Inc. He is a founder of Axonyx Inc., acquired by Torrey Pines Therapeutics, Inc. He is a founder of Entia Biosciences, Inc., which designs and develops natural organic antioxidant food-based products to be used as nutritional supplements in humans and animals. He is Founder and President of Northwest Medical Research Partners, Inc., a company specializing in the identification and acquisition of breakthrough pharmaceutical and nutraceutical products. Dr. Hausman is a Member of the Board of Governors of New York University School of Medicine Alumni Association. About Ludwig Enterprises, Inc.: Ludwig Enterprises, "The Genetic Language Company", ™ is a publicly traded Genomics Technology Holding Company with Precision Genomics, Inc. and mRNA for Life, Inc. as wholly owned subsidiaries. Advancements in Biotechnology and Artificial Intelligence (AI) presents cutting-edge genomic tools, unheard-of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to potentially assist in improved patient outcomes and, in some cases, potentially even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic methodology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, pre-eclampsia, and cancer. This early analysis may assist patients and doctors to manage illness before it progresses and causes serious health problems. Precision Genomics' innovative testing approach is not only practical but also has the potential to save the healthcare industry billions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig Enterprises is potentially poised to significantly impact how we think about disease and live longer, healthier lives. More Info: SAFE HARBOR Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements are not a guarantee of future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition. CONTACT: Ludwig Enterprises, Inc Marvin S. Hausman, M.D. Chief Executive Officer CEO@LUDG.us SOURCE: Ludwig Enterprises, Inc. View source version on accesswire.com:

LONDON, April 26 /PRNewswire-FirstCall/ -- - Board Aligned to Company's Growth Strategy Curidium Medica plc, ('Curidium' or the 'Company') today announced changes to its Board of Directors. Dr. Gosse B. Bruinsma, M.D. has been appointed as an Executive Director and will become Executive Chairman, subject to shareholder approval as a director, immediately after the next Annual General Meeting on the 23rd May 2007. Dr. Phyllis E. Whiteley, Ph.D has been appointed as a Non-Executive Director. These changes are in line with the Company's objectives outlined in its AIM admission document. As a result Mr. Simon Cartmell, Non-Executive Chairman, will retire from the board after the Company's next Annual General Meeting to concentrate on his other extensive business interests. Dr. Anne T. Bruinvels continues as the Company's Chief Executive Officer. Gosse B. Bruinsma most recently served as Director and President and CEO of Axonyx Inc. in New York until he successfully merged the company with a private USA-based company in October 2006. During his tenure with Axonyx he also fulfilled the role of Chief Operating Officer from February 2001 to September 2003 and President from September 2003 until the merger. He was also President of Axonyx Europe BV between October 2000 and October 2006. For more than 20 years Gosse has held senior level positions at a number of biopharmaceutical and pharmaceutical service companies, including European Medical Director for Zambon, Milan, Vice President for Medical and Regulatory Affairs for ClinTrials Research, UK, Medical Director for Forest Laboratories in New York, and General Manager and VP Development for Chrysalis Clinical Services Europe based in Switzerland. Gosse received his undergraduate degree from McGill University, Montreal and his medical degree from the University of Leiden, The Netherlands. He served as Chairman and Chief Executive Officer of OXIS International in 2004. Gosse currently serves as Director on the Supervisory Board of Agendia BV based in Amsterdam and advises several other companies at executive and Board level. Phyllis E. Whiteley, PhD is a director of the US Personalized Medicine Coalition and she was until recently Senior Vice President of Business Development and Licensing of Perlegen Inc., a US based personalized medicine company. Prior to Perlegen, Phyllis was Vice President Strategic Portfolio Management, Global Pharma Research Strategy for F. Hoffman La Roche. During her ten year tenure with Roche she held various positions including Vice President Business Development and Global Licensing Director based in Basel, Switzerland and other research leadership positions including Therapeutic Area Head. Prior to Roche, Phyllis was with Merck. She holds a Ph.D., Pharmacology from Washington University, St. Louis, Missouri. "I am very pleased that Dr Bruinsma and Dr Whiteley have joined our Board" said Dr Anne Bruinvels, Chief Executive Officer of Curidium Medica plc, "Their extensive industry experience and network will be invaluable in leveraging the significant recent results associated with our Homomatrix(r) technology and the growth opportunities that now present themselves to the Company. I would like to thank Simon Cartmell for his invaluable contribution over the past three years and, on behalf of the Company, wish him every success in the future." Blue Oar Securities Plc About Curidium Curidium is a company focused on identifying targeted medicines to treat patients more effectively. Through the application of its proprietary technology, Homomatrix(r), Curidium analyses biological data (gene expression /protein data) from patients suffering from complex or multi-factorial diseases. Patient populations with complex disorders are known to be heterogeneous and only certain sub-groups of patients respond to a specific treatment. Curidium believes that Homomatrix will ultimately allow for the development of the right drug for the right patient. The Company files patents around the genes and drug targets that are associated with the specific subgroups of patients. Further information on Curidium can be found at the Company's website: . Curidium Medica PLC CONTACT: For further information please contact: Anne Bruinvels,+44-(0)-20-7554-8790, CEO, Curidium Medica plc, Rob Smith,+44-(0)-20-7554-8793, Finance Director, Curidium Medica plc, Rhodri Cruwys,+44-(0)-20-7448-4400

NEW YORK--(BUSINESS WIRE)--Jan. 24, 2006--Axonyx Inc. (NASDAQ: AXYX) announced today completion of the ascending single dose Phase I trial with Posiphen(TM), in clinical development for the treatment of Alzheimer's disease progression. This double-blind, placebo controlled study of Posiphen in healthy men and women sought to establish well tolerated doses. Posiphen appears to be well tolerated at single doses up to and including 80mg. Blood levels of Posiphen associated with this study were higher than those associated with beneficial effects on beta-amyloid metabolism in animal models. The build-up of beta-amyloid (A beta) is generally believed to be causative of the dementia of Alzheimer's disease. No serious adverse events were reported at any dose level.